Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
DIVIS LABORATORIES TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DIVIS LABORATORIES Mar-23 |
TEVA PHARMA Dec-13 |
DIVIS LABORATORIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 4,641 | 3,486 | - | |
Low | Rs | 2,730 | 3,028 | - | |
Sales per share (Unadj.) | Rs | 292.6 | 2,000.5 | - | |
Earnings per share (Unadj.) | Rs | 68.7 | 125.0 | - | |
Cash flow per share (Unadj.) | Rs | 81.6 | 286.7 | - | |
Dividends per share (Unadj.) | Rs | 30.00 | 109.40 | - | |
Avg Dividend yield | % | 0.8 | 3.4 | 24.2% | |
Book value per share (Unadj.) | Rs | 480.9 | 2,222.2 | - | |
Shares outstanding (eoy) | m | 265.47 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 12.6 | 1.6 | 773.7% | |
Avg P/E ratio | x | 53.7 | 26.1 | 205.9% | |
P/CF ratio (eoy) | x | 45.2 | 11.4 | 397.5% | |
Price / Book Value ratio | x | 7.7 | 1.5 | 522.9% | |
Dividend payout | % | 43.7 | 87.5 | 49.9% | |
Avg Mkt Cap | Rs m | 978,378 | 2,761,843 | 35.4% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 9,750 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,744.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,357.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 77,675 | 1,696,422 | 4.6% | |
Other income | Rs m | 3,447 | 0 | - | |
Total revenues | Rs m | 81,122 | 1,696,422 | 4.8% | |
Gross profit | Rs m | 23,691 | 464,566 | 5.1% | |
Depreciation | Rs m | 3,432 | 137,123 | 2.5% | |
Interest | Rs m | 20 | 33,320 | 0.1% | |
Profit before tax | Rs m | 23,686 | 294,122 | 8.1% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -193,075 | -0.0% | |
Tax | Rs m | 5,453 | -3,591 | -151.8% | |
Profit after tax | Rs m | 18,234 | 105,974 | 17.2% | |
Gross profit margin | % | 30.5 | 27.4 | 111.4% | |
Effective tax rate | % | 23.0 | -1.2 | -1,885.5% | |
Net profit margin | % | 23.5 | 6.2 | 375.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 97,437 | 1,145,757 | 8.5% | |
Current liabilities | Rs m | 15,331 | 999,197 | 1.5% | |
Net working cap to sales | % | 105.7 | 8.6 | 1,223.5% | |
Current ratio | x | 6.4 | 1.1 | 554.3% | |
Inventory Days | Days | 8 | 91 | 9.2% | |
Debtors Days | Days | 842 | 96 | 878.2% | |
Net fixed assets | Rs m | 51,128 | 554,089 | 9.2% | |
Share capital | Rs m | 531 | 4,176 | 12.7% | |
Net worth | Rs m | 127,671 | 1,884,403 | 6.8% | |
Long term debt | Rs m | 0 | 867,418 | 0.0% | |
Total assets | Rs m | 148,565 | 3,876,868 | 3.8% | |
Interest coverage | x | 1,209.5 | 9.8 | 12,307.7% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.5 | 0.4 | 119.5% | |
Return on assets | % | 12.3 | 3.6 | 342.0% | |
Return on equity | % | 14.3 | 5.6 | 254.0% | |
Return on capital | % | 18.6 | 4.9 | 376.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 24,597 | 270,322 | 9.1% | |
From Investments | Rs m | -27,076 | -95,786 | 28.3% | |
From Financial Activity | Rs m | -7,972 | -324,269 | 2.5% | |
Net Cashflow | Rs m | -10,451 | -149,733 | 7.0% |
Compare DIVIS LABORATORIES With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare DIVIS LABORATORIES With: HESTER BIOSCIENCES CHEMO PHARMA ASTRAZENECA PHARMA ERIS LIFESCIENCES LACTOSE INDIA
Asian share markets are mixed today after US shares extended their losing streak to the longest since January 2024.